Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation.

  • 2004-07
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 93(1)
    • Robert D Gray
    • Kay Haggart
    • Daniel K C Lee
    • Steven Cull
    • Brian J Lipworth

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 21
Population
35 patients (14 men and 21 women) with IAR
Methods
A double-blind, placebo-controlled, crossover study; butterbur, 50 mg twice daily, or placebo for 2 weeks
Blinding
Double-blind
Duration
2 weeks
Funding
Unclear

Background

Butterbur (Petasites hybridus) contains the active ingredient petasin, which exhibits antileukotriene and antihistamine activity. Previous studies of intermittent allergic rhinitis (IAR) have demonstrated a comparable response to butterbur compared with a histamine H1-receptor antagonist on the 36-Item Short-Form Health Survey quality-of-life score. However, there has been no placebo-controlled study of the effects of butterbur use on objective and subjective outcomes in IAR.

Objective

To evaluate the effects of treatment with butterbur vs placebo on objective and subjective outcomes in IAR.

Methods

A double-blind, placebo-controlled, crossover study was carried out during the grass pollen season in Tayside, Scotland. Thirty-five patients (14 men and 21 women) with IAR received butterbur, 50 mg twice daily, or placebo for 2 weeks. Domiciliary measurements were taken in the morning and evening for peak nasal inspiratory flow (PNIF) (the primary outcome variable), nasal and eye symptoms, and rhinoconjunctivitis-specific quality-of-life score.

Results

Butterbur treatment had no significant effect on PNIF, total nasal symptom score, eye symptom score, or quality of life compared with placebo use. Mean (SEM) morning and evening PNIF values were 107 (6) and 114 (6) L/min, respectively, for butterbur vs 105 (6) and 117 (6) L/min for placebo. Mean (SEM) morning and evening total nasal symptom scores (maximum total score, 12) were 3.4 (0.4) and 3.5 (0.4), respectively, for butterbur vs 3.7 (0.3) and 3.8 (0.4) for placebo.

Conclusions

There was no significant clinical efficacy of butterbur use vs placebo use on objective and subjective outcomes in IAR. Further studies are now indicated to investigate the use of butterbur in persistent allergic rhinitis.

Research Insights

  • butterbur→Improved Peak Nasal Inspiratory Flow

    Butterbur treatment had no significant effect on PNIF, total nasal symptom score, eye symptom score, or quality of life compared with placebo use.

    Effect
    Neutral
    Effect size
    Small
    Dose
    50 mg twice daily
  • butterbur→Improved Rhinoconjunctivitis-Specific Quality of Life

    Butterbur treatment had no significant effect on PNIF, total nasal symptom score, eye symptom score, or quality of life compared with placebo use.

    Effect
    Neutral
    Effect size
    Small
    Dose
    50 mg twice daily
  • butterbur→Reduced Eye Symptom Score

    Butterbur treatment had no significant effect on PNIF, total nasal symptom score, eye symptom score, or quality of life compared with placebo use.

    Effect
    Neutral
    Effect size
    Small
    Dose
    50 mg twice daily
  • butterbur→Reduced Total Nasal Symptom Score

    Butterbur treatment had no significant effect on PNIF, total nasal symptom score, eye symptom score, or quality of life compared with placebo use.

    Effect
    Neutral
    Effect size
    Small
    Dose
    50 mg twice daily
Back to top